Hendel H, Hénon N, Lebuanec H, Lachgar A, Poncelet H, Caillat-Zucman S, Winkler C A, Smith M W, Kenefic L, O'Brien S, Lu W, Andrieu J M, Zagury D, Schächter F, Rappaport J, Zagury J F
Laboratoire de Physiologie Cellulaire, Université Pierre et Marie Curie, Paris, France.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):381-6. doi: 10.1097/00042560-199812010-00009.
The Genetics of Resistance to Infection by HIV-1 (GRIV) cohort represents 200 nonprogressor/slow-progressor (Slowprog) and 90 fast-progressor (Fastprog) HIV-1-infected patients. Using this unique assembly, we performed genetic studies on three recently discovered polymorphisms of CCR5, CCR2, and SDF1, which have been shown to slow the rate of disease progression. The increased prevalence of mutant alleles among Slowprogs from the GRIV cohort was significant for CCR5 (p < .0001) but not for CCR2 (p = .09) or SDF1 (p = . 12), emphasizing the predominant role of CCR5 as the major HIV-1 coreceptor. However, the prevalence of the CCR2 mutant allele (64I) was significantly increased among Slowprogs homozygous for wild-type CCR5 compared with Fastprogs (p = .04). The prevalence of double mutants SDF1-3'A/3'A genotypes was also increased among Slowprogs homozygous for wild-type CCR5 compared with Fastprogs (p = .05). The effects of the CCR2 and SDF1 mutations are overshadowed by the protective effects of the CCR5 deletion. Predictive biologic markers such as CD4 cell counts or viral load in the Slowprog population did not show significant differences between Slowprog groups with wild-type or mutant alleles for the three genes. Thus, our data suggest that the effects of these genes are exerted earlier in infection and no longer evident in the Slowprog of the GRIV cohort whose average duration of HIV infection is 12 years. We conclude that these genes, whose products serve as viral coreceptors or their ligands, may play a role early in infection and delay the onset of disease. However, among Slowprogs, whose duration of infection is >8 years, they are no longer influential for maintenance of their longterm nonprogression status. Other genetic determinants may be responsible for late protective effects.
HIV-1感染抗性遗传学(GRIV)队列包括200名非进展型/进展缓慢型(Slowprog)和90名进展快速型(Fastprog)HIV-1感染患者。利用这一独特样本,我们对CCR5、CCR2和SDF1最近发现的三种多态性进行了遗传学研究,这些多态性已被证明可减缓疾病进展速度。GRIV队列中Slowprog患者中突变等位基因的患病率增加,CCR5的差异具有显著性(p <.0001),但CCR2(p =.09)或SDF1(p =.12)无显著性差异,这突出了CCR5作为主要HIV-1共受体的主要作用。然而,与Fastprog患者相比,野生型CCR5纯合的Slowprog患者中CCR2突变等位基因(64I)的患病率显著增加(p =.04)。与Fastprog患者相比,野生型CCR5纯合的Slowprog患者中SDF1 - 3'A/3'A基因型双突变体的患病率也有所增加(p =.05)。CCR2和SDF1突变的影响被CCR5缺失的保护作用所掩盖。在Slowprog人群中,诸如CD4细胞计数或病毒载量等预测性生物学标志物在具有这三个基因野生型或突变等位基因的Slowprog组之间未显示出显著差异。因此,我们的数据表明,这些基因的作用在感染早期发挥,而在GRIV队列平均HIV感染持续时间为12年的Slowprog患者中不再明显。我们得出结论,这些基因的产物作为病毒共受体或其配体,可能在感染早期发挥作用并延迟疾病发作。然而,在感染持续时间>8年的Slowprog患者中,它们对维持其长期非进展状态不再有影响。其他遗传决定因素可能负责后期的保护作用。